Back to Search
Start Over
Immunologic mechanisms of a short-course of Lolium perenne peptide immunotherapy: A randomized, double-blind, placebo-controlled trial.
- Source :
-
The Journal of allergy and clinical immunology [J Allergy Clin Immunol] 2019 Sep; Vol. 144 (3), pp. 738-749. Date of Electronic Publication: 2019 Mar 05. - Publication Year :
- 2019
-
Abstract
- Background: A 3-week short-course of adjuvant-free hydrolysates of Lolium perenne peptide (LPP) immunotherapy for rhinoconjunctivitis with or without asthma over 4 physician visits is safe, well tolerated, and effective.<br />Objective: We sought to investigate immunologic mechanisms of LPP immunotherapy in a subset of patients who participated in a phase III, multicenter, randomized, double-blind, placebo-controlled trial (clinical.govNCT02560948).<br />Methods: Participants were randomized to receive LPP (n = 21) or placebo (n = 11) for 3 weeks over 4 visits. Grass pollen-induced basophil, T-cell, and B-cell responses were evaluated before treatment (visit [V] 2), at the end of treatment (V6), and after the pollen season (V8).<br />Results: Combined symptom and rescue medication scores (CSMS) were lower during the peak pollen season (-35.1%, P = .03) and throughout the pollen season (-53.7%, P = .03) in the LPP-treated group compared with those in the placebo-treated group. Proportions of CD63 <superscript>+</superscript> and CD203c <superscript>bright</superscript> CRTH2 <superscript>+</superscript> basophils were decreased following LPP treatment at V6 (10 ng/mL, P < .0001) and V8 (10 ng/mL, P < .001) compared to V2. No change in the placebo-treated group was observed. Blunting of seasonal increases in levels of grass pollen-specific IgE was observed in LPP-treated but not placebo-treated group. LPP immunotherapy, but not placebo, was associated with a reduction in proportions of IL-4 <superscript>+</superscript> T <subscript>H</subscript> 2 (V6, P = .02), IL-4 <superscript>+</superscript> (V6, P = .003; V8, P = .004), and IL-21 <superscript>+</superscript> (V6, P = .003; V8, P = .002) follicular helper T cells. Induction of FoxP3 <superscript>+</superscript> , follicular regulatory T, and IL-10 <superscript>+</superscript> regulatory B cells were observed at V6 (all P < .05) and V8 (all P < .05) in LPP-treated group. Induction of regulatory B cells was associated with allergen-neutralizing IgG <subscript>4</subscript> -blocking antibodies.<br />Conclusion: For the first time, we demonstrate that the immunologic mechanisms of LPP immunotherapy are underscored by immune modulation in the T- and B-cell compartments, which is necessary for its effect.<br /> (Copyright © 2019. Published by Elsevier Inc.)
- Subjects :
- Adult
Asthma immunology
B-Lymphocytes, Regulatory immunology
Conjunctivitis immunology
Desensitization, Immunologic
Double-Blind Method
Female
Humans
Immunoglobulin E blood
Immunoglobulin G blood
Male
Peptides immunology
Rhinitis, Allergic, Seasonal immunology
T-Lymphocytes, Helper-Inducer immunology
T-Lymphocytes, Regulatory immunology
Young Adult
Allergens immunology
Asthma therapy
Conjunctivitis therapy
Lolium immunology
Peptides therapeutic use
Pollen immunology
Rhinitis, Allergic, Seasonal therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1097-6825
- Volume :
- 144
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- The Journal of allergy and clinical immunology
- Publication Type :
- Academic Journal
- Accession number :
- 30844425
- Full Text :
- https://doi.org/10.1016/j.jaci.2019.02.023